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Abstract
Zika virus infection is associated with the development of Guillain-Barre´ syndrome (GBS), a
neurological autoimmune disorder caused by immune recognition of gangliosides and other
components at nerve membranes. Using a high-throughput ELISA, we have analyzed the
anti-glycolipid antibody profile, including gangliosides, of plasma samples from patients with
Zika infections associated or not with GBS in Salvador, Brazil. We have observed that Zika
patients that develop GBS present higher levels of anti-ganglioside antibodies when compared
to Zika patients without GBS. We also observed that a broad repertoire of gangliosides was
targeted by both IgM and IgG anti-self antibodies in these patients. Since Zika virus infects
neurons, which contain membrane gangliosides, antigen presentation of these infected cells
may trigger the observed autoimmune anti-ganglioside antibodies suggesting direct infection-
induced autoantibodies as a cause leading to GBS development. Collectively, our results
establish a link between anti-ganglioside antibodies and Zika-associated GBS in patients.
Author summary
Zika virus infection can trigger the development of Guillain Barre´ syndrome (GBS), a neu-
rological autoimmune disorder mediated by antibodies recognizing gangliosides in nerve
membranes. Mechanisms such as molecular mimicry have been identified as a cause for
GBS development in certain infections, such as Campylobacter jejuni, but the broad self
reactivity observed during GBS suggests a role for alternative mechanisms. Our finding
that Zika patients with GBS present higher levels of anti-ganglioside antibodies compared
to uncomplicated Zika patients in Brazil points to these auto-antibodies as a trigger for
GBS in these patients. These findings further support infection-induced autoantibodies as
a factor contributing to GBS development, adding novel mechanisms for GBS develop-
ment beyond molecular mimicry.
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Introduction
Zika virus is an arbovirus (arthropod-borne) of the Flaviviridae family, which like dengue
viruses and alphavirus chikungunya virus is transmitted by Aedes mosquitoes. Although dis-
covered in 1947 in Uganda, the first large Zika virus outbreak was reported in Micronesia in
2007 [1] followed by the 2014 French Polynesia outbreak [2] and the massive Latin American
outbreak in 2015, which was first reported in Brazil and spread across the Americas [3]. Dur-
ing this outbreak, alarming Zika-associated complications, such as microcephaly and Guillain
Barre´ syndrome (GBS) were reported [4, 5].
GBS is an inflammatory neuropathy and the most common cause of neuromuscular paraly-
sis in the world [6]. The etiology of GBS is unknown but its development has been highly asso-
ciated with post-infection autoimmune responses against gangliosides in peripheral nerves.
Gangliosides are sialated glycosphingolipids found in neuronal membranes and are involved
in different neuronal functions. Autoimmune antibodies recognizing gangliosides are found
in a high proportion of patients with GBS (62% [12]) and are thought to contribute to neuro-
nal pathology inducing complement-mediated axonal injury and demyelination [6]. Molecular
mimicry has been proposed as a likely mechanism in infection-induced GBS, where antibodies
generated against microbial antigens with structural similarities to specific gangliosides would
cross-react with host gangliosides in neuronal membranes. A classic example is GBS associated
with Campylobacter jejuni infection [7]. Zika virus was added to the list of GBS-associated
pathogens due to the high incidence reported during the 2015 Latin America outbreak [8];
however, Zika virus-associated GBS shows anti-gangliosides antibodies (anti-GA1) that cannot
be attributed to molecular mimicry [9], as described for C. jejuni [7], suggesting alternative
mechanisms for the generation of autoantibodies as a result of Zika infection.
During many autoimmune disorders, such as rheumatoid arthritis, autoantibodies play an
essential pathological role in mediating the disease. Interestingly, increased levels of IgG auto-
antibodies against the ganglioside GD3 have been observed in patients with acute Zika infec-
tion and without neurologic manifestations such as GBS [10]. Some GBS manifestations have
also been associated with elevated levels of autoantibodies such as anti-ganglioside antibodies
that can target peripheral nerves [11, 12], but the association of these antibodies with Zika-
induced GBS remains unclear.
In this study we evaluate the antibody reactivity levels against 17 different glycolipids,
including mostly gangliosides, presented in single and combination form, in the plasma of
Zika-infected patients from one of the locations of the 2015 outbreak in Salvador, Brazil. We
observed that Zika-associated GBS patients have significantly higher levels of plasma anti-gly-
colipid antibodies compared to non-GBS Zika-infected patients. We also observed a broad
repertoire of glycolipids, including gangliosides, that were targeted by both IgM and IgG anti-
self antibodies. Collectively, these results established a link between anti-ganglioside antibodies
and Zika-associated GBS patients.
Methods
Ethics statement
This study was approved by the institutional review board of Instituto Gonc¸alo Moniz-Fio-
cruz–n˚1184454/2015. All participants were adults, agreed to participate in the study and
signed Informed Consent.
Study design and sample collection
Cases of GBS and encephalitis associated with arbovirus infection and Zika infection without
neurological symptoms were enrolled in a surveillance study in neurological units of two
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reference hospitals in Salvador, Bahia, Brazil, from May 2015 to April 2016, during the Zika
outbreak in this area [13]. The study population were patients with acute neurological syn-
dromes admitted to neurology sectors of participating hospitals. Patients with Zika infections
but no neurological signs were recruited as part of a surveillance program for Zika infections
in the same hospitals. All patients with neurological syndromes were evaluated by the
researcher neurologist and the diagnosis of GBS was established according to international cri-
teria [14]. The inclusion criteria were: (1) Patients with symptoms compatible with GBS and
its variants or encephalitis. The diagnosis of GBS, Miller-Fisher syndrome (MFS) and its vari-
ants [14]; and encephalitis [15] was predetermined by disease-specific criteria. [2] Patients that
reported acute exantemathous or fever illness in the 4 weeks before onset of neurologic symp-
toms. Electromyography and nerve conduction studies were performed in patients with GBS.
See Table 1 for details regarding the timing of neurologic symptoms and sample collection in
relations to symptoms of arbovirus infection.
Serological analysis
Detection of specific anti-Zika, anti-chikungunya, and anti-dengue IgG antibodies and anti-
dengue and anti-chikungunya IgM antibodies were performed using indirect enzyme-linked
Table 1. Patient diagnosis and detection of Zika RNA (by RT-PCR) and arbovirus IgM and IgG by ELISA.
Patient ID Zika GBS Time to
neuro
onset
(days)1
Time to sample collection
(days)2
Chikungunya Dengue
RNA NT3 IgM IgG Type RNA IgM IgG RNA IgM IgG
Acute Zika
(n = 3)
1 + + + - 2 - - - - - +
2 - + - - 7 - - - - - -
3 + - - - 3 - - - - - -
4 months after Zika (n = 2) 4 - - + - 122 - - - -
5 - - + - 146 - - - +
Zika + encephalitis (n = 3) 6 - + + - 6 7 - - + - + +
7 - + + - 6 5 - - - - - -
8 - + + - 5 13 - - - - - +
Zika + GBS
(n = 7)
9 (2)4 - + + BFP5 10 10/466 - - - - - +
10 (2) - + + Classic 33 17/57 - - - - - +
11 - - + Classic 4 6 - - - - - -
12 - + + + Classic 11 5 - - - - - +
13 - + + + Classic 10 23 - - - - - +
14 - + + + MFS7 33 5 - - - - - +
15 - - + Classic 3 35 - - - - - +
GBS unknown etiology
(n = 1)
16 - - - Classic 14 7 - - - - - +
Chikungunya (n = 2) 17 - - + Classic 20 - + + - - +
18 - - + Classic 20 - + + - - +
1Days between onset arboviral symptoms (or fever for patient 16) and neurological onset
2Days between onset of arboviral symptoms and sample collection
3Plaque reduction neutralization test
4Number of samples collected from an individual patient
5Bifacial weakness with paresthesias (BFP)
6Days between onset of arboviral symptoms and sample collection for first and second samples
7Miller Fisher syndrome (MFS)
https://doi.org/10.1371/journal.pntd.0007695.t001
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immunosorbent assays (ELISAs) (Euroimmun, Lu¨berg, Germany), in accordance with the
manufacturer protocol. An IgM antibody-capture ELISA (MAC-ELISA), provided by the
Arbovirus Reference Collection division of the Centers for Disease Control and Prevention
(CDC), was used in accordance with the established CDC protocol. Detection of RNA for
Zika, chikungunya and dengue virus were performed by reverse transcriptase-PCR following
published methods [16–18]. Patient samples positive for Zika plaque reduction neutralization
test (PRNT) and/or positive for Zika IgM and negative for dengue IgM by ELISA (CDC) were
considered positive for Zika infection. Patient 11 was considered positive for Zika infection
because it showed positive Zika IgG and negative dengue IgG. Only in patient 15, which is pos-
itive for Zika and dengue IgG, lack of cross-reactivity with anti-dengue antibodies could not
be confirmed. Zika infection was considered acute when samples were positive for Zika RNA
(by RT-PCR, [18] and/or Zika IgM (by ELISA). Biological samples, including blood, were col-
lected upon hospital admission or 4 months after the onset of symptoms, as indicated. Data
management was performed using REDCap 6.18.1 - 2018 Vanderbilt University.
Ganglioside ELISAs
Costar 3700 384-well ELISA plates were coated with single or mixes of Glycolipids
(Matreya, Sigma) at 20 μg/ml in 200 proof Molecular Biology ethanol using an Agilent
Bravo system in a BSL-2 hood. The lipids used were: sphingomyelin (SPM), phosphatidyl-
serine (PS), sulfatide (SULF), globoside (GS), Trihexosylceramide (CTH-hydroxi fatty acid)
(THCH), Trihexosylceramide (CTH non-hydroxy fatty acid)(THCHN), galactocerebroside
(GALC), and the gangliosides GM1, GM2, GM3, GA1, GD1A, GD1B, GD2, GD3, GT1B
and GQ1B. Plates were then allowed to evaporate at RT after >16 h of incubation at 4˚C.
Plates were washed 3 times with PBS 0.05% tween 20 and then blocked overnight with PBS
supplemented with 3% BSA. Plasma from patients was diluted at 1:100 in blocking buffer
and incubated for 2 h at 37 ˚C. Plates were washed again 3 times and incubated with anti-
human IgM/IgG-HRP (Abcam) for 1 h at 37 ˚C. Plates were washed 3 more times and TMB
substrate (BD Biosciences) was added until desired color was obtained. Reaction was
stopped with Stop buffer (Biolegend) and absorbance was read at 450 nm. The optical den-
sity at 450 nm was compared with the same dilution (1:100) of a positive plasma sample
(sample ID: 9b) that was used as reference to calculate relative units (RU). Two negative
controls were included in each of the ELISA plates run: (1) The plasma of a healthy US con-
trol donor was used in duplicated wells in the ELISA for each glycolipid and combinations.
The average of the 2 determinations for each glycolipid and combinations was used as back-
ground for each glycolipid and subtracted from each value. (2) The reactivity of each plasma
sample in wells coated with PBS supplemented with 3% BSA. The value of eight indepen-
dent wells for each plasma sample was obtained. It was observed that the variation between
the eight replicates with each plasma samples was <0.02 for all samples and the variation
between the average values for the different plasma samples was <0.0002. The reactivity of
all plasma samples to BSA was considered constant and was not subtracted from assay val-
ues. The reactivity to wells coated with only glycolipids coating buffer (ethanol) was not
considered since it results in high unspecific background for all samples. The secondary
antibody, TMB and stop solution was added using the peristaltic pump on the Biotek
EL406. Washes were also done using the 96-head washer on the EL406. Validation of the
automated 384-well ELISAs was performed using a similar protocol in 96-well plates with
manual pipetting. Five different plasma samples (9b, 10a, 11, 14 and 16) of GBS patients
were tested with five randomly chosen glycolipids (SPM, GS, GM1, GD3 and SULF). The
variation between the two assays was found to be lower than 0.008 for each of the
glycolipids.
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Statistical analysis
Data were analyzed using Prism (GraphPad Software). Unpaired t-test was used to identify sta-
tistical differences between groups of samples. For determination of number of antigens recog-
nized per sample and number of positive samples recognizing each ganglioside, reactivity of
samples was considered positive if the OD value was at least the average of control background
wells plus three times the standard deviation.
Results
Zika-associated GBS is one of the most serious complications associated with this infection.
Our main goal in this study is to compare the prevalence and specificities of anti-ganglioside
antibodies in a cohort of Zika-associated GBS patients (n = 7) compared to Zika-infected
patients without GBS (n = 8). Among these, some patients presented with encephalitis (n = 3)
or were Zika-infected with no neurological symptoms, either in acute phase (n = 3) or 4
months after the onset of symptoms (n = 2). The median of days between the onset of arboviral
and neurological symptoms was 10 days for the Zika-associated GBS patients (Table 1).
Strong anti-ganglioside antibody response in Zika-associated GBS patients
Using a novel high throughput ELISA approach, we assessed the plasma of these patients for
their reactivity (IgM and IgG) against different gangliosides. The reactivity to combinations of
glycolipids has been described to be higher than the reactivity to single ones, possibly due to
the formation of complex antigenic structures [12]. We therefore analyzed reactivity against 17
lipids, mostly glycolipids including gangliosides described to be associated with GBS [6], alone
or their 139 double combinations. We first performed an overall analysis of all the patient sam-
ples to determine the levels of ganglioside reactivity in their plasma using a high throughput
ELISA approach to detect anti-ganglioside IgM and IgG antibodies. These assays showed
increased anti-ganglioside reactivity in the plasma of Zika-associated GBS patients compared
to Zika patients without GBS (Fig 1A–1C). Collectively, these results showed an enriched anti-
ganglioside antibody response in the plasma of Zika-associated GBS patients compared to
Zika-infected controls.
Additionally, we analyzed one sample from a GBS patient of unknown etiology who was
negative for Zika, dengue and chikungunya infections, which showed a similar profile to Zika-
associated GBS patients.
Since a previous report described that the plasma of GBS patients presented higher anti-
body reactivity to complex glycolipids compared to individual ones, we analyzed the responses
to individual versus 2-by-2 combined glycolipids. We did not find any significant differences
between the average reactivity of any of the plasma samples to individual or combined glyco-
lipids (Fig 2).
We also analyzed the plasma of two GBS patients with active chikungunya virus infection
(IgM+) and previous Zika infection (IgG+). The plasma from these patients did not present
strong reactivity against gangliosides, in contrast to Zika-associated GBS patients (Fig 3).
Broad ganglioside specificity in the plasma of Zika-associated GBS patients
We further dissected the anti-ganglioside reactivity patterns observed in Zika-infected patients
with or without GBS. A detailed analysis of antigen reactivity showed that patients that devel-
oped GBS recognized a significantly higher number of antigens (single and combined ganglio-
side mixes) compared to patients without GBS (Fig 4A). The highest number of antigens
recognized was found in a GBS patient reacting significantly to>100 different single
Autoantibodies in Zika infection with GBS
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Fig 1. Reactivity of plasma samples from Zika patients with or without GBS. (a) Heatmap of antibody reactivity to
single lipids and lipid combinations. Results from plasma of patients with uncomplicated Zika (acute (I: patients 1–3)
or 4 months after the onset of symptoms (II: patients 4–5), with Zika infection and encephalitis (III: patients 6–8), with
Zika infection and GBS (patients 9–15; a and b indicate different time points of sampling for the same patient) or with
GBS from unidentified etiology (patient 16). Antigen lipids used: sphingomyelin (SPM), phosphatidylserine (PS),
sulfatide (SULF), globoside (GS), Trihexosylceramide (CTH-hydroxi fatty acid) (THCH), Trihexosylceramide (CTH
non-hydroxy fatty acid)(THCHN), galactocerebroside (GALC), and the gangliosides GM1, GM2, GM3, GA1, GD1A,
GD1B, GD2, GD3, GT1B and GQ1B. (b) Average of reactivity values for all lipids and combinations in samples from
patients with Zika with or without GBS. Samples of plasma from patients with uncomplicated acute Zika (black
circles), 4 months after the onset of symptoms from a Zika infection (blue circles), Zika with encephalitis (red circles)
and Zika with GBS (black squares). A sample of plasma from a patient with GBS but no Zika infection (unidentified
etiology) (green square) was not considered in the average. (c) Average of reactivity values for each lipid and lipid
Autoantibodies in Zika infection with GBS
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gangliosides/combinations while all non-GBS patients reacted significantly against 2 or fewer
antigens. When we analyzed which specific gangliosides had an enriched reactivity across the
Zika infected patients (either in single or combination form) we observed a broad reactivity to
different gangliosides and other glycolipids (Fig 4B). These results suggest a broad anti-gangli-
oside antibody response in Zika-associated GBS patients, independent of combinations.
Isotypes of antibodies in the anti-ganglioside response in Zika-associated
GBS high responders
Our initial screen of anti-ganglioside reactivity evaluated the presence of overall IgM/IgG anti-
bodies in the plasma of the Zika-associated GBS patients. We further analyzed the samples by
validating the responses observed in six highly responsive patients, from the Zika-associated
GBS group. We also dissected this response by determining IgM and IgG reactivities separately
(Fig 5). The results of these assays showed high levels of both anti-ganglioside IgM and IgG in
the plasma of the patients compared to control plasma. Additionally, these assays validated the
strong broad reactivity of the Zika-GBS patient plasma against a high number of gangliosides
(Fig 4). Collectively, these results confirm the presence of IgM and IgG anti-ganglioside anti-
bodies in the plasma of Zika-associated GBS patients. Our findings demonstrate broad reactiv-
ity to glycolipids with stronger responses to specific gangliosides.
Discussion
GBS is one of the most serious complications associated with Zika infection. Neurological
symptoms appear shortly after a transient Zika infection resulting in the development of GBS
[9, 11, 19, 20]. In this study a median of 10 days before the onset of neurological symptoms
combinations in samples from patients with Zika with or without GBS. Data are expressed as RU values. �p< 0.05,
��p< 0.01, ���p< 0.001, ����p< 0.0001, when the groups are compared to each other by unpaired t-test.
https://doi.org/10.1371/journal.pntd.0007695.g001
Fig 2. Reactivity to single glycolipids versus combinations. Average antibody reactivity of samples from patients
with Zika or Zika + GBS was analyzed for single and combined glycolipids. Each dot represents the average reactivity
to all single or combined glycolipids for each plasma sample. No significant (ns) differences between single and
combined groups were found when compared by unpaired t-test.
https://doi.org/10.1371/journal.pntd.0007695.g002
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was observed, which is similar to a previous report (6 days) [9]. Although Zika virus infection
has been reported to lead to development of GBS in patients, little is known about the patho-
genesis of this syndrome. Different autoantibodies have been identified as mediators of pathol-
ogy during different autoimmune disorders, such as anti-nuclear antibodies during Systemic
Lupus Erythematosus [21]. Indeed, GBS is considered an autoimmune syndrome due to the
immune destruction of peripheral nerve components such as gangliosides [19, 22, 23]. Genera-
tion of anti-ganglioside antibodies and other autoantibodies has been reported in non-Zika
infection-induced GBS, such as the classical one induced by the bacterium C. jejuni [7].
Because anti-ganglioside autoantibodies are implicated in the pathogenesis of GBS [6], we
sought to determine whether anti-ganglioside antibodies were selectively increased in Zika-
infected patients with GBS as opposed to Zika-infected controls with self-limited illness.
Our initials results show a potent broad reactivity against single and combination of 17 dif-
ferent gangliosides compared to non-GBS Zika infected patients. These anti-ganglioside
Fig 3. Reactivity of samples from plasma of two GBS patients with active chikungunya virus infection and
previous Zika infection (IgG+). (a) Heatmap of plasma reactivity to single lipids and lipid combinations. Results from
plasma from patients with active chikungunya virus infection (IgM+) and previous Zika infection (IgG+) and GBS
compared with Zika infection alone and GBS. (b) Average of reactivity values for all lipids and combinations in
samples from these patients. (c) Average of reactivity values for each lipid and lipid combinations in samples from
these patients. Data are expressed as RU values. �p< 0.05, ��p< 0.01, ���p< 0.001, ����p< 0.0001, when the groups
are compared to each other by unpaired t-test.
https://doi.org/10.1371/journal.pntd.0007695.g003
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antibodies were both of the IgM and IgG isotypes. Both anti-ganglioside IgG and IgM have
been suggested to have a pathological role during different non-Zika infection induced GBS
patients [24]. The mechanism by which these anti-gangliosides lead to pathology is poorly
understood. The significant increase in anti-ganglioside IgM/IgG antibodies in patients with
GBS compared to non-GBS Zika-infected patients suggests a role for these antibodies in medi-
ating the disease.
A recent study assessed a similar relationship of ganglioside reactivity in Zika-associated
GBS patients in French Polynesia [9]. This study found an increase in general anti-ganglioside
reactivity against a different set of gangliosides tested by a different method of combinatorial
glycolipid microarray. Our results show reactivity against different individual and combina-
tion of gangliosides hence illustrating the diversity in the anti-ganglioside response induced in
Fig 4. Antigenic analysis of the reactivity of plasma from Zika patients with or without GBS. (a) Reactivity to
glycolipids, presented single or as combinations, of the plasma samples from Zika patients (identified from 1 to 15; a
and b indicate different time points of sampling for the same patient). The patient with GBS of unknown etiology (16)
is marked with a red rectangle. Data is presented as number of single lipids or combinations that were recognized by
plasma samples of each patient. (b) Reactivity to single glycolipids in plasma samples of Zika-associated GBS patients
(n = 9). A sample was considered positive if its value was higher than the average plus 3 three times the standard
deviation of the values obtained for the eight Zika without GBS patient samples.
https://doi.org/10.1371/journal.pntd.0007695.g004
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a different cohort of Zika-associated GBS patients. We did not observe any enhancement of
reactivity whenever specific gangliosides were tested individually or in combination, which
may be attributed to the different methods used for detection (microarray versus ELISA).
In addition to Zika virus, other arbovirus infections like dengue and chikungunya have also
been reported to lead to autoimmunity and neurological problems such as GBS [25–30]. A
large percentage of the patients in our study had previous, but not active, dengue infections, as
indicated by the differential anti-dengue IgM and IgG reactivity. Previous dengue infections
are expected in this area of Brazil where prevalence is 86% in adults and where preexisting
high antibody titers to dengue virus have been associated with reduced risk of Zika infection
[31].
We also assessed the plasma of two GBS patients with active chikungunya virus infection
and previous Zika infection (IgG+). When we assessed the plasma of these patients for anti-
ganglioside reactivity, our results demonstrated levels of anti-ganglioside antibodies signifi-
cantly lower than GBS patients with an active Zika infection. It is possible that anti-ganglioside
antibodies in the circulation induced during a Zika infection decrease over time and are no
longer present in these patients. The role of an active chikungunya infection is unclear.
It is well established that Zika can infect neurons [32–34], including peripheral motor
nerves/nerve roots, which have high abundance of different gangliosides. Direct infection of
neurons would target these cells for phagocytosis by antigen presenting cells, enabling presen-
tation of many auto antigens, such as gangliosides, along with virus antigens, resulting in an
antibody response against both. Increased immune recognition of virus-infected neuronal cell
antigens could be at the basis of Zika–induced GBS. Immune response against direct neural
infection would be consistent with the observation that GBS tends to be an early complication
of Zika. Accordingly, a recent studied showed how antiviral CD8+ T-cells mediated nerve
damage leading to paralysis in Zika-infected mice [35]. Additionally, immune mediated
Fig 5. IgM and IgG reactivity of plasma from high-responder Zika patients with GBS. Heatmap of plasma IgM and
IgG reactivity to individual glycolipids, expressed as optical density values from the specific ELISAs. The patient with
GBS of unknown etiology (16) is marked with a red rectangle. Control uninfected plasma (C).
https://doi.org/10.1371/journal.pntd.0007695.g005
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neurological damage was also reported in fatal cases of Zika-induced microcephaly [36], pro-
viding additional evidence of an immune component contributing to the neuronal damage
leading to GBS. Accordingly, plasma from Brazilian Zika-infected patients recognized GD3
from neurons in retina tissues [10]. These patients were found to have high titers of anti-gan-
glioside antibodies, mainly anti-GD3 IgG antibodies. Nevertheless, mechanistic studies are
needed to test this hypothesis and elucidate the role anti-ganglioside antibodies might have in
Zika-induced GBS.
Although we observed wide reactivity to gangliosides, our results also showed differential
reactivity to some gangliosides in the plasma of Zika-associated GBS patients. When we dis-
sected these responses by validating them with single ganglioside ELISAs, we confirmed a
strong reactivity against specific gangliosides such as GA1. Interestingly, GA1 also had the
highest reactivity from the French Polynesia study as assessed by a different method of combi-
natorial glycolipid microarray [9]. However, in a different study in India with Zika-infected
GBS patients, the most commonly recognize ganglioside was GT1b [37]. Collectively, our
results suggest that, in a minor subset of infected patients, Zika infection causes neuronal dam-
age that triggers an auto-immune antibody response against neuron-derived ganglioside anti-
gens, which contributes to the pathogenesis of GBS.
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